Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy

Hypertension
Susumu OgawaSadayoshi Ito

Abstract

We tested the hypothesis that blockade of angiotensin II type 1 receptors reduces oxidative stress markers in parallel with urinary albumin and type IV collagen excretions. Sixty-six diabetic patients with nephropathy were randomly assigned to either the angiotensin II receptor blocker (ARB; n=33) or trichlormethiazide (n=33) group. The majority of patients had been treated with angiotensin-converting enzyme inhibitors or calcium channel blockers for > or =1 year before the present study. Reduction of blood pressure was not different between the 2 groups, and HbA1c levels did not change over the study period (8 weeks). Treatment with ARB (candesartan 8 mg/day, n=11 or valsartan 80 mg/day, n=22) for 8 weeks reduced the levels of plasma monocyte chemoattractant protein 1, interleukin 6, urinary 8-epi-prostaglandin F2alpha, 8-hydroxydeoxyguanosine, albumin, and type IV collagen, whereas the levels of these markers were not altered with trichlormethiazide (2 mg/day). Significant correlation was observed between the reduction of the urinary 8-epi- prostaglandin F2alpha and 8-hydroxydeoxyguanosine and those of the urinary albumin and type IV collagen. Subjects with large oxidative stress had large reduction rates because of ARB admin...Continue Reading

References

Mar 1, 1996·Diabetes Care·D GiuglianoG Paolisso
Jul 18, 2002·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·James D KrierLilach O Lerman
Aug 7, 2002·Circulation·Giancarlo VibertiUNKNOWN MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators
Nov 28, 2002·JAMA : the Journal of the American Medical Association·Matthew J Sheetz, George L King
Jan 7, 2003·American Journal of Physiology. Lung Cellular and Molecular Physiology·P K McFawnJ T Fisher
Mar 1, 2003·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Tina ChabrashviliChristopher S Wilcox
Sep 12, 2003·Trends in Pharmacological Sciences·Hua CaiDavid G Harrison
Oct 29, 2003·Hypertension·Yoshihiro Taniyama, Kathy K Griendling
Nov 19, 2003·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yasuaki DohiRyuzo Ueda
Aug 18, 2004·Circulation·Danilo FliserUNKNOWN EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators
Dec 8, 2004·Journal of the American Society of Nephrology : JASN·Giuseppe RemuzziUNKNOWN RENAAL Study Group

❮ Previous
Next ❯

Citations

Sep 4, 2008·Current Hypertension Reports·Ivonne Hernandez Schulman, Leopoldo Raij
Mar 6, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Sadayoshi ItoTakefumi Mori
May 2, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Satoshi EndoSadayoshi Ito
Jun 18, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tetsunori SaikawaUNKNOWN DDV investigators
Dec 17, 2010·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Susumu OgawaSadayoshi Ito
Nov 11, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hiroki FujitaYuichiro Yamada
Nov 17, 2012·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Mai YanagiSatoshi Umemura
Jul 4, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Minoru SatohNaoki Kashihara
Oct 9, 2009·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Keisuke IshizawaToshiaki Tamaki
Mar 5, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ausilia MaioneGiovanni F M Strippoli
Dec 1, 2009·Toxicological Sciences : an Official Journal of the Society of Toxicology·Shih-Ping HsuChiang-Ting Chien
Apr 9, 2010·Journal of Hypertension·Hiroyuki KoboriLuis Gabriel Navar
Nov 26, 2009·Clinical and Experimental Pharmacology & Physiology·Daisuke Nakano, Atsuhiro Ichihara
Dec 14, 2011·Clinical and Experimental Pharmacology & Physiology·Takefumi MoriSadayoshi Ito
Aug 18, 2009·American Journal of Physiology. Heart and Circulatory Physiology·Scott T McEwenJulian H Lombard
Oct 24, 2006·American Journal of Nephrology·Naoki NakagawaKenjiro Kikuchi
Feb 18, 2010·American Journal of Nephrology·Maki UrushiharaHiroyuki Kobori
Sep 2, 2011·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Keisuke Ishizawa
Jun 2, 2007·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Susumu OgawaSadayoshi Ito
Jun 23, 2011·International Journal of Nephrology and Renovascular Disease·John A D'EliaLarry A Weinrauch
May 14, 2009·Vascular Health and Risk Management·Alessandra Del FiorentinoRoberto Pedrinelli
Feb 1, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Susumu OgawaSadayoshi Ito
Jan 30, 2008·Free Radical Biology & Medicine·Siu-Wai ChoiBernadette M Hannigan
Aug 1, 2014·Experimental Gerontology·Chung-Hao LinJeremy D Walston
Jun 9, 2007·Current Opinion in Cardiology·Hirofumi HitomiAkira Nishiyama
Jun 23, 2011·Clinical and Experimental Nephrology·Yang-Gyun KimChun-Gyoo Ihm
Nov 1, 2011·Clinical and Experimental Nephrology·Sadayoshi Ito
Oct 15, 2014·International Journal of Molecular Sciences·Yoshifumi Saisho
Oct 20, 2009·Current Medical Research and Opinion·Francesco LocatelliTevfik Ecder
Oct 16, 2008·Clinical and Experimental Hypertension : CHE·Tsukasa NakamuraKoichi Node
May 29, 2010·Kidney International·Minoru Satoh
Apr 10, 2012·Transplantation Proceedings·T IshiiT Nishioka
Aug 11, 2011·Molecular and Cellular Endocrinology·Arun Prasath LakshmananMakoto Kodama
Jan 13, 2011·Advances in Chronic Kidney Disease·Peter N Van Buren, Robert Toto
Mar 5, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Csaba András Dézsi
Oct 30, 2008·Journal of the American Society of Hypertension : JASH·Hiroyuki KoboriTatsuo Yamamoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.